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Abstract. Using celecoxib as lead, two novel series of sulfonamides incorporating the 
pyridotriazolopyrimidine scaffold have been synthesized and evaluated in vitro as inhibitors 
against four relevant human (h) carbonic anhydrases (CAs, EC 4.2.1.1), the cytosolic and 
ubiquitous hCA I and II as well as the transmembrane hCA IV and hCA IX. Most of the 
reported sulfonamides acted as efficient, low micromolar inhibitors of hCAI, II and IV, 
whereas they displayed higher efficacy in inhibiting the tumor-associated isoform hCA IX. 
Many derivates herein reported showed better hCA IX versus hCA II selectivity ratios 
compatred to celecoxib or acetazolamide. Considering isoform IX is a validated target for the 
diagnosis and treatment of hypoxic tumors, discovery of selective CA IX inhibitors represents 
a promising step to unveil a more effective cancer therapies. 
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1. Introduction: 
Celecoxib I, a sulfonamide acting as dual cyclooxygenase – carbonic anhydrase (CA, EC 
4.2.1.1) inhibitor,1 was considered to be an attractive target for designing CA inhibitors (CAIs) 
which may possess a dual action on these two families of enzymes involved in various 
pathologies which cross-freact in some cases (e.g., glaucoma, cancer, arthritis).2-6. Celecoxib 
shows a nanomolar affinity for the cytosolic human (h) isoform hCA II (Ki= 21 nM), inhibiting 
even better the tumour associated enzymes hCA XI (Ki=16 nM) and hCA XII (Ki=18 nM).1 
These enzymes were recently validated as antitumor/antoimetastatic targets with one 
compounds (SLC-0111) in Phase Ib/II clinical trials.2,3 The X-ray crystal structure of celecoxib 
bound CA II (PDB code: 6cox) reported by one of our groups,1 afforded the deep understanding 
of the groups important for interaction with the CA II active site. The sulfonamide group of I 
was observed to be coordinated to Zn+2 in a tetrahedral coordination geometry, whereas the 
trifluormethyl group occupied the hydrophobic pocket, located in one half of the active site.1a 
Unexpectedly, the p-toyl moiety of the drug was observed to point towards the hydrophilic half 
of the active site, making favourable contacts with residues Asn67, Glu69 and Gln92.
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Figure 1. Structure of some reported sulphonamide CAIs of types I-III. 
The presence of the 2-phenyl substitutent in the triazolobenzenesulfonamide derivative II 
(Figure 1) elicited moderate to strong inhibition of four CAs, namely, CA I, CA II, CA IX and 
CA XII, with KI ranging between 0.041 to 0.542 µM.7 Modification of the phenyl group to a 
ferrocene based moiety, as in compound III led to a decrease of the activity towards CA I and 
CA XII, while retaining a good inhibitory effect against CA II (Ki = 0.036 µM) and CA IX (Ki 
= 0.065 µM).7
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Figure 2: Schematic representation of possible interactions with CA IX active site (PDB: 
4q06)1a of A. Celecoxib and B. Designed scaffold with possible extra interaction points 
C.Target PTP derivatives 
An analysis of a modelling study, of celecoxib and CA IX protein, showed a similar mode 
of interaction between the sulfonamide and the active site, as in the hCA II – celecoxib complex 
analysed by X-ray crystallography (Figure 2A). Our current model of designing selective CAIs 
is based on designing a scaffold that can be substituted with less polar groups (Ar1 and Ar2 in 
Figure 2B), in order to fill in the unoccupied hydrophobic pocket (Figure 2B). In view of the 
aforementioned facts and in continuation of our earlier work on the design of inhibitors of these 
enzymes,1-3 it was envisaged to incorporate the bulky pyridotriazolopyrimidine (PTP) scaffold 
as tail to the benzene-sulfonamide motif. We aimed to exploit the unoccupied hydrophobic 
region shown in Figure 2A, within the active site of CA IX, hypothesizing that the aryls at 
position 6 and 8 of the PTP scaffold may interact in a favorable manner with the enzyme active 
site, as shown schematically in Figure 2C. We report herein the synthesis and the carbonic 
anhydrases inhibition evaluation of the new such derivatives, incorporating the bulky PTP 
scaffold. 
2. Results and discussion:
2.1. Chemistry: 
Our proposed synthetic methodology to the desired pyridotriazolopyrimidine scaffold 
containing sulfonamide moiety is depicted in Scheme 1, Scheme 2 and Scheme 3. The synthesis 
of the 6-amino-2-thiouracil (3) was accomplished as reported by refluxing ethyl cyanoacetate 
(1) with thiourea (2) in sodium ethoxide.8 The condensation of the 6-amino-2-thiouracil (3) 
with different aromatic α-β unsaturated ketones, β-enaminones, diketones and aldehydes was 
reported as convenient and efficient strategy to synthesize substituted pyrido[2,3-
d]pyrimidines.9-13 Quiroga et al.12 reported that the reaction of the 6-amino-2-thiouracil (3) 
with different chalcones in refluxing DMF resulted in the formation of the pyrido[2,3-
d]pyrimidines 5 and/or 6. When the reaction performed under argon atmosphere for short 
period of time, it yielded mainly the 2-thioxo-2,3,5,8-tetrahydropyrido[2,3-d]pyrimidin-4(1H)-
one derivative 6. However, under exposure to air for long time in refluxing DMF, the oxidized 
isomer 5 was formed. In addition, the substitutions of phenyl groups of the chalcone affect the 
product selectivity where the electron withdrawing group preferentially favours the formation 
of the oxidized form 5.12 
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Scheme 1: Reagents and conditions: (i) NaOEt/Ethanol (ii) dry DMF /reflux 15h
The synthesis of the key pyrido[2,3-d]pyrimidines 5a-j was accomplished via reacting 6-
amino-2-thiouracil 3 and different α-β unsaturated aromatic ketones 4a-j14 in refluxing dry 
DMF under air in 40-65% yields (Scheme 1). The structures assigned to compounds 5a-j were 
confirmed by 1H and 13C NMR. 1H NMR spectra of the synthesized pyrido[2,3-d]pyrimidines 
showed the presence of a singlet at δ 7.56-8.07 ppm integrated to the pyridine ring proton and 
two NH singlet signals at δ 12.23-12.41 and 12.90-13.10 ppm corresponding to two NHs of the 
pyrimidine ring. Furthermore, 13C NMR spectra of 5a-c revealed the signals of the pyridine H 
at δ 108.20-108.27 ppm and the signal of thioxo carbon at δ 175.41-175.43 ppm.
The hydrazonoyl chlorides 11a and 11b synthesis were started with the chlorination of 
the active methylene group of acetylacetone 7a and ethyl acetoacetate 7b using sulphuryl 
chloride to afford the α-chloroacetyl derivatives 8a and 8b, as described by Alihn in 1878.15 
Then by applying Japp-Klingemann coupling of the aforementioned α-chloroacetyl derivatives 
(8a and 8b) with the diazonium salts of sulfanilamide 10, we have got the acetyl derivative 11a 
and the ester derivative 11b in reasonable yields (65 and 72%, respectively) (Scheme 2).16
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Scheme 2: Reagents and conditions: (i) SO2Cl2/ 0 °C (ii) NaNO2/HCl (iii) CH3COONa/ 0 °C
The reaction of the pyrido[2,3-d]pyrimidine thiones and hydrazonoyl halides have been 
extensively studied.16-19 This reaction proceeds via 1,3-dipolar cycloaddition of hydrazonoyl 
chlorides with dipolarophile thiones.17 
A literature review of this reaction almost exclusively prefers isomer 16 over 15 (Scheme 
3). This suggest that the reaction process through the cyclo-addition of carbon 2 and nitrogen 
3 of the pyrido[2,3-d]pyrimidine thiones with the hydrazonoyl chloride derivative in presence 
of base (Scheme 3).17 The reaction mechanism was postulated to start with S-alkylation of the 
thiouracil derivative to afford the thiohydrazontes 12. In the presence of base, the 
nucleophilicity of the terminal hydrazone N increases and the compound undergoes Chapman-
like rearrangement to give the corresponding thiohydrazide 13. The latter thiohydrazide was 
cyclized in situ to afford 15 or 16. 1H NMR spectra of compounds 16a-t showed disappearance 
of the two NH singlet signals. The acetyl derivatives displayed singlet signals resonating at δ 
2.63-2.68 ppm representing the acetyl CH3 protons. Meanwhile, 1H NMR of the ester analogues 
showed a typical triplet-quartet pattern of the ethyl protons at δ 1.24-1.31 and 4.42-4.43 ppm. 
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Scheme 3: Reagents and conditions: (i) Dioxane, TEA, reflux, 6-14h.
Analysis of the 13C NMR spectra of the novel synthesized derivatives indicated that we 
preferentially synthesized isomer 16 rather than isomer 15. It was reported that the chemical 
shift of the carbonyl carbon in pyrimidin-4-one derivatives is relying on the adjacent 
environment.20 For instance, if the adjacent nitrogen is pyrrole type (sp3-hybridized) (as in 16) 
the carbonyl carbon signals of the pyrimidinone ranged from 160-165. Nevertheless, if the 
neighbouring atom is a pyridine type (as in 15) chemical shift of the carbonyl carbon usually 
appears at 170-175 ppm. 13C NMR spectral data of compounds 16a-t revealed carbonyl carbon 
signals of the pyrimidinone at 159.90 and 163.21 ppm. This result is in line with previous 
reports of the reactions of hydrazonoyl halides with similar condensed 2- 
thioxopyridopyrimidines.16-21
2.2. Carbonic anhydrase inhibition:
All the synthesized derivatives 16a-16t were evaluated for their efficacy in inhibiting four 
relevant CA isoforms, i.e., hCA I, II, IV and IX, by using the stopped flow carbon dioxide 
hydrase assay22, in comparison to acetazolamide (AAZ) as a standard CAI.
In general, all the assayed compounds displayed good inhibitory action against the reported 
hCA isoforms, with KI spanning from the low micromolar to the low-medium nanomolar range. 
In detail, the following structure−activity-relationship (SAR) can be gathered from the data 
reported in Table 1, for each tested isoform: 
Table 1: Inhibition data of human CA isoforms hCA I, II, IV and IX with sulfonamides 16a-
16t, celecoxib and the standard sulfonamide inhibitor acetazolamide (AAZ) by a stopped flow 
CO2 hydrase assay.22
KI (µM)Compound Structure R1 R2
hCAI hCA II hCA IV hCA IX
16a I -COCH3        -H         3.79 0.59 3.00 0.18
16b I -COOC2H5 -H NA 3.54 4.62 3.26
16c I -COCH3        -F 6.64 1.19 3.58 0.25
16d I -COOC2H5 -F 9.35 4.66 4.90 3.24
16e I -COCH3        -Cl 7.42 2.03 3.56 0.35
16f I -COOC2H5 -Cl 9.16 3.65 4.70 1.46
16g I -COCH3        -OCH3 5.50 0.74 3.01 0.33
16h I -COOC2H5 -OCH3 7.37 1.58 NA 1.45
16i I -COCH3        -NO2 5.52 0.86 2.92 0.33
16j I -COOC2H5 -NO2 7.29 3.05 3.56 2.46
16k II -COCH3        -H 6.78 0.73 4.79 1.12
16l II -COOC2H5 -H 6.82 1.41 NA 1.90
16m II -COCH3        -F 2.65 0.35 2.45 0.19
16n II -COOC2H5 -F NA 1.48 3.96 1.62
16o II -COCH3        -Cl NA 3.43 2.52 0.99
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*Mean from 3 different assays, by a stopped flow technique (errors were in the range of 
±5−10% of the reported values).
(i) The cytosolic isoform hCA I was inhibited by most sulfonamides herein reported in the low 
micromolar range (KIs between  2.64 and 9.35 μM), with the exception of compounds 16b, 
16n and 16o which did not inhibit hCA I up to 100 μM. Only derivative 16r showed a 
submicromolar hCA I inhibitory efficacy (KIs 0.85 μM). Such results ascribed to the prepared 
compounds better inhibitory efficacy than those of celecoxib, although worsened compared to 
the clinically used sulfonamide AAZ.
(ii) The physiologically dominant isoform hCA II was efficiently inhibited by all sulfonamides 
16a-16t, with KI values ranging between 0.35 and 4.66 μM (Table 1). Despite the impossibility 
to drawing a clear SAR, probably elicited by the rather flat inhibitory tendency revealed against 
hCA II, it is worth noting the submicromolar inhibitors 16a, 16g, 16i, 16k, 16m, 16r and 16s 
(KIs between  0.35 and 86 μM). All of them bear the acetyl group in position R1 (except 16r), 
thus highlighting the better impact of such a group on the binding efficacy, compared to the 
carboxymethyl moiety. 
(iii) Likewise hCA I, most of the reported sulfonamides showed comparable effectiveness in 
inhibiting the membrane-associated isoform hCA IV, with KI values spanning in the low 
micromolar range (2.23- 4.90 μM), except 16h and 16l which did not inhibit hCA I up to 100 
μM. Only the nitro derivative 16s, which appended the acetyl and the thienyl groups at the PTP 
scaffold, acted as a potent hCA IV inhibitor with a KI of 0.20 μM.
(iv) Finally, the tumor-associated isoform hCA IX was potently inhibited by the most of the 
reported sulfonamides with KI reaching the low-medium nanomolar range (0.16 – 3.26 μM). 
In particular, the acetyl bearing derivatives 16a, 16c, 16e, 16g and 16i from series I and 16m 
and 16s from series II, displayed a nanomolar inhibitory profile (KIs  of 0.18, 0.25, 0.35, 0.33, 
0.33, 0.19 and 0.16 μM, respectively) likened to the corresponding carboxyethyl analogues (KIs  
16p II -COOC2H5 -Cl 2.64 1.71 4.33 0.39
16q II -COCH3        -OCH3 9.04 2.98 2.23 0.42
16r II -COOC2H5 -OCH3 0.85 0.72 4.25 0.38
16s II -COCH3        -NO2 3.02 0.50 0.20 0.16
16t II -COOC2H5 -NO2 8.71 1.75 2.98 1.10
Celecoxib >10 0.021 0.29 0.02
AAZ 0.25 0.01 0.07 0.03
of 3.26, 3.24, 1.46, 1.45, 2.46, 1.62 and 1.10 μM, respectively). Conversely, only the 
carboxyethyl bearing compounds 16p and 16r demonstrated to be better hCA IX inhibitors (KIs  
of 0.39  and 0.38 μM) in comparison to the acetyl analogues 16o and 16q (KIs  of 0.99 and 0.42 
μM). Moreover, the data in Table 1 undeniably highlighted the positive effect on the inhibitory 
efficacy against hCA IX obtained by swapping the 4-Cl-phenyl group with the thienyl one.
(v) Despite the not enviable efficacy that sulfonamides 16a-16t showed against the tumor-
associated isoform (celecoxib and AAZ displayed KIs of 0.02 and 0.03 μM), it is reasonable  
to focus the attention on the interesting selective profile they possess against hCA IX versus 
hCA II (Table 2). Indeed, it is satisfying to note that most of the reported compounds displayed 
a selectivity ratio hCA IX/hCA II from two-fold to fourteen-fold higher than celecoxib or AAZ. 
Only 16k, 16l and 16n were non-selective hCA IX over hCA II inhibitors. On the other hand, 
all the acetyl PTP sulfonamides from the series I and 16k and 16m from series II were shown 
to possess much better selectivity for the tumor-associated isoform hCA IX over hCA IV, 
compared to the corresponding carboxyethyl analogues and AAZ, while exhibited comparable 
selectivity ratio with celecoxib. A different behaviour may be highlighted for the remaining 
derivatives of series II. In fact, the carboxyethyl bearing sulfonamides 16p, 16r and 16t were 
more selective inhibitors of hCA IX over hCA IV in comparison to their acetyl analogues. In 
addition, 16p and 16r displayed selectivity ratio hCA IX/IV comparable to celecoxib, being 
four-fold better than AAZ.
(vi) As more than once highlithed here, the data reported in Table 1 clearly demonstrate that 
the replacement of the acetyl group in position R1 by the carboxyethyl moiety generally 
worsened the inhibition profiles of derivatives 16a-16t depending on the substituents Ar1, R2 
and the considered isoform.It is reasonable to hypothesize that such a diminished inhibitory 
efficacy of the carboxyethyl derivatives in comparison to the acetyl ones might derive from the 
steric hyndrance aroused by the PTP. Indeed, such a bulky core may lead to a rather rigid and 
fixed positioning of the tricyclic scaffold within the active site pocket, obviously depending on 
the substituents Ar1 and R2. Hence, in most cases the replacement of the acetyl group with the 
bigger carboxyethyl moiety may cause clashes with amino acid residues from the hydrophobic 
pocket, worsening thus the inhibitory activity.
Table 2: Selectivity ratios for the inhibition of hCA IX over hCA II and hCA IX over hCA IV 
for the compounds 16a-16t reported in the paper:
Compound
Selectivity ratio
3. Conclusions
Two novel series of sulfonamides, 16a-16j and 16k-16t, containing the 
pyridotriazolopyrimidine scaffold have been synthesized and evaluated in vitro as inhibitors 
against four relevant hCAs, comprising the cytosolic and ubiquitous isozymes hCA I and II as 
well as the transmembrane hCA IV and hCA IX, the last one a validated antitumor drug target. 
Most of the reported sulfonamides acted as good, low micromolar inhibitors of hCA I, II and 
IV, whereas they displayed a better efficacy in inhibiting the tumor-associated isoform hCA 
IX. Many derivatives herein reported highlighted better selectivity ratios for inhibiting hCA IX 
over hCA II than celecoxib and AAZ. Conversely, some sulfonamides among the two series 
demostrated a comparable selectivity for hCA IX over hCA IV, similar to celecoxib, whereas 
being 3 to 6-fold better than AAZ. Considering that isoform hCA IX is a validated target for 
the diagnosis and treatment of cancers, discovery of selective inhibitors represents a promising 
step to unveil a more effective cancer therapy, and moreover the obtained SAR might further 
help in the design of novel, isoform-selective inhibitors.
hCA IX/hCA II hCA IX/hCA IV
16a 3.35 16.90
16b 1.08 1.42
16c 4.68 14.12
16d 1.44 1.51
16e 5.78 10.14
16f 2.49 3.21
16g 2.23 9.12
16h 1.09 NA
16i 2.62 8.86
16j 1.24 1.45
16k 0.65 4.26
16l 0.75 NA
16m 1.84 12.83
16n 0.91 2.44
16o 3.45 2.53
16p 4.37 11.08
16q 7.06 5.29
16r 1.86 11.00
16s 3.13 1.23
16t 1.58 2.70
Celecoxib 1.05 14.5
AAZ 0.48 2.96
4. Experimental
4.1 Chemistry:
4..1.1. General:
Melting points were measured with a Stuart apparatus and were uncorrected. The NMR spectra 
were recorded by Varian Gemini-300BB 300, 400 and 500 MHz FT-NMR spectrometers 
(Varian Inc., Palo Alto, CA). 1H spectra were run at 300, 400 and 500 MHz and 13C spectra 
were run at 75, 100 and 125 MHz, respectively, in deuterated dimethylsulphoxide (DMSO-d6). 
Chemical shifts (δH) are reported relative to TMS as internal standard. All coupling constant 
(J) values are given in hertz. The abbreviations used are as follows: s, singlet; d, doublet; t, 
triplet, m, multiplet. Microanalyses were carried out using Perkin Elmer PE 2400 CHN 
Elemental Analyzer and the results were within ±0.4%. Analytical thin layer chromatography 
(TLC) on silica gel plates containing UV indicator was employed routinely to follow the course 
of reactions and to check the purity of products. All reagents and solvents were purified and 
dried by standard techniques. 6-Amino-2-thiouracil (3),23 hydrazonoyl chlorides 11a, 11b,18 
pyrido[2,3-d]pyrimidines 5d, 5e, 5g  were prepared according to the literature procedure.12
4.1.2. General procedure for preparation of 5-aryl-7-(thiophen-2-yl / 4-chlorophenyl)-2-
thioxo-2,3-dihydropyrido[2,3-d]pyrimidin-4(1H)-one (5a-j) and spectral data is depicited in 
the supplementary file.
4.1.3. General procedure for preparation of target compounds (16a-t). To a mixture of 5-aryl-
7-(thiophen-2-yl / 4-chlorophenyl)-2-thioxo-2,3-dihydropyrido[2,3-d]pyrimidin-4(1H)-one 
(5a-j) (1 mmol) and the appropriate hydrazonoyl chloride 11a, b (1 mmol) in dioxane (30 mL), 
triethylamine (0.14 mL, 1 mmol) was added. The reaction mixture was refluxed until the 
starting materials were fully consumed or until conversion was observed to stall (monitored by 
TLC). The solvent was removed under vacuum and the residue was triturated with methanol. 
The formed solid was washed thoroughly with water, filtered then crystallized from 
DMF:EtOH [v:v, 1:1] or subjected to flash chromatography (methanol/dichloromethane, 1:10) 
to give 16a-t. Compounds 16k and 16l were previously synthesized in our laboratory.18 
4.1.3.1. 4-(3-Acetyl-8-(4-chlorophenyl)-5-oxo-6-phenylpyrido[2,3-d][1,2,4]triazolo[4,3-
a]pyrimidin-1(5H)-yl)benzenesulfonamide (16a): Yield: 46%, m.p. >300 ºC; 1H NMR (500 
MHz, DMSO-d6) δ ppm: 2.66 (s, 3H, -CH3), 7.46-7.48 (m, 5H, Ar-H), 7.54 (br.  s, 2H, -
SO2NH2, D2O exchangeable), 7.60 (d, J = 8.5 Hz 2H, Ar-H), 7.78 (s, 1H, pyridine H), 8.10 (d, 
J = 9.0 Hz 2H, Ar-H), 8.35 (d, J = 8.5 Hz 2H, Ar-H), 8.48 (d, J = 9.0 Hz 2H, Ar-H); 13C NMR 
(125 MHz, DMSO-d6) δ ppm: 30.11, 108.04, 119.31, 120.69, 127.71, 128.19, 128.61, 128.93, 
129.43, 130.14, 136.20, 136.44, 139.26, 139.58, 142.23, 142.70, 147.67, 155.12, 155.52, 
160.27, 160.31, 188.03; Anal. Calcd for C28H19ClN6O4S: C, 58.90; H, 3.35; N, 14.72. Found: 
C, 59.20; H, 3.56; N, 14.52.
4.1.3.2. Ethyl 8-(4-chlorophenyl)-5-oxo-6-phenyl-1-(4-sulfamoylphenyl)-1,5-
dihydropyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidine-3-carboxylate (16b): Yield: 57%, m.p.  
>300 ºC oC; 1H NMR (500 MHz, DMSO-d6) δ ppm: 1.29 (t, J = 7 Hz, 3H, -COOCH2CH3), 
4.43 (q, J = 7 and 7, 2 Hz, -COOCH2CH3), 7.45-7.47 (m, 5H, Ar-H), 7.53 (br. s, 2H, -SO2NH2, 
D2O exchangeable), 7.59 (d, J = 8.5 Hz, 2H, Ar-H), 7.77 (s, 1H, pyridine H), 8.09 (d, J = 8.5 
Hz, 2H, Ar-H), 8.34 (d, J = 8.5 , 2H, Ar-H), 8.44 (d, J = 8.5 , 2H, Ar-H); 13C NMR (125 MHz, 
DMSO-d6) δ ppm: 13.72, 63.63, 107.39, 118.77, 120.26, 127.21, 127.72, 128.18, 128.47, 
128.94, 129.65, 135.73, 135.87, 135.98, 138.76, 139.03, 142.24, 146.63, 154.57, 154.76, 
156.12, 159.79, 159.90; Anal. Calcd for C29H21ClN6O5S: C, 57.95; H, 3.52; N, 13.98. Found: 
C, 57.76; H, 3.87; N, 13.82.
4.1.3.3. 4-(3-Acetyl-8-(4-chlorophenyl)-6-(4-fluorophenyl)-5-oxopyrido[2,3-
d][1,2,4]triazolo[4,3-a]pyrimidin-1(5H)-yl)benzenesulfonamide (16c): Yield: 51%, m.p. >300 
ºC; 1H NMR (500 MHz, DMSO-d6) δ ppm: 2.67 (s, 3H, -CH3), 7.28 (t, J = 8.5, 2H, Ar-H), 
7.52-7.55 (m, 4H, 2Ar-H + -SO2NH2, D2O exchangeable), 7.59 (d, J = 8.5 , 2H, Ar-H), 7.79 (s, 
1H, pyridine H), 8.09 (d, J = 8.5 , 2H, Ar-H), 8.34 (d, J = 8.5 , 2H, Ar-H), 8.47 (d, J = 8.5 , 2H, 
Ar-H); 13C NMR (125 MHz, DMSO-d6) δ ppm: 29.63, 107.56, 114.51 (2JF-C = 21.38 Hz), 
118.88, 120.20, 127.21, 128.93, 129.64, 130.66 (3JF-C = 8.38 Hz), 135.26, 135.29, 135.76, 
135.88, 138.74, 141.73, 142.24, 146.81, 153.50 (1JF-C = 198.00 Hz), 159.79, 161.24, 163.19, 
187.51; Anal. Calcd for C28H18ClFN6O4S: C, 57.10; H, 3.08; N, 14.27. Found: C, 57.46; H, 
3.36; N, 14.56.
4.1.3.4. Ethyl 8-(4-chlorophenyl)-6-(4-fluorophenyl)-5-oxo-1-(4-sulfamoylphenyl)-1,5-
dihydropyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidine-3-carboxylate (16d): Yield: 62%, m.p. 
>300 ºC; 1H NMR (500 MHz, DMSO-d6) δ ppm: 1.30 (t, J = 7Hz, -COOCH2CH3), 4.43 (q, J 
= 7 and 7.5 Hz, 2H, -COOCH2CH3), 7.29 (t, J = 9 Hz, 2H, Ar-H), 7.52-7.55 (m, 4H, 2Ar-H + 
-SO2NH2, D2O exchangeable), 7.61 (d, J = 8.5 , 2H, Ar-H), 7.81 (s, 1H, pyridine H), 8.09 (d, J 
= 8.5 , 2H, Ar-H), 8.35 (d, J = 9 , 2H, Ar-H), 8.44 (d, J = 9 , 2H, Ar-H); 13C NMR (125 MHz, 
DMSO-d6) δ ppm: 13.74, 63.65, 107.46, 114.53 (2JF-C = 21.88 Hz), 118.86, 120.28, 127.22, 
128.97, 129.68, 130.69, 130.76 (3JF-C = 8.63 Hz), 135.28, 135.77, 135.87, 135.96, 138.74, 
142.27, 146.62, 153.46, 154.85 (1JF-C = 159.18 Hz), 159.86, 159.90, 161.27, 163.21; Anal. 
Calcd for C29H20ClFN6O5S: C, 56.27; H, 3.26; N, 13.58. Found: C, 56.56; H, 3.59; N, 13.62.
4.4.3.5. 4-(3-Acetyl-6,8-bis(4-chlorophenyl)-5-oxopyrido[2,3-d][1,2,4]triazolo[4,3-
a]pyrimidin-1(5H)-yl)benzenesulfonamide (16e): Yield: 40%, m.p. >300 ºC; 1H NMR (500 
MHz, DMSO-d6) δ ppm: 2.66 (s, 3H, -CH3), 7.50-7.55 (m, 6H, 4Ar-H + -SO2NH2, D2O 
exchangeable), 7.62 (d, J = 8.5 Hz 2H, Ar-H), 7.82 (s, 1H, pyridine H), 8.10 (d, J = 9.0 Hz 2H, 
Ar-H), 8.36 (d, J = 8.5 Hz 2H, Ar-H), 8.48 (d, J = 9.0 Hz 2H, Ar-H); 13C NMR (125 MHz, 
DMSO-d6) δ ppm: 30.36, 108.18, 118.00, 120.96, 127.91, 128.42, 129.67, 130.37, 131.05, 
133.76, 136.49, 136.59, 138.57, 139.43, 142.42, 142.95, 147.57, 153.93, 155.80, 160.48, 
160.64, 188.26; Anal. Calcd for C28H18Cl2N6O4S: C, 55.55; H, 3.00; N, 13.88. Found: C, 55.79; 
H, 3.16; N, 13.59.
4.4.3.6. Ethyl 6,8-bis(4-chlorophenyl)-5-oxo-1-(4-sulfamoylphenyl)-1,5-dihydropyrido[2,3-
d][1,2,4]triazolo[4,3-a]pyrimidine-3-carboxylate (16f): Yield: 52%, m.p. >300 ºC; 1H NMR 
(500 MHz, DMSO-d6) δ ppm: 1.30 (t, J = 7, 3H, -COOCH2CH3), 4.45 (q, J = 7 and 7.5, 2H, -
COOCH2CH3), 7.49-7.54 (m, 5H, Ar-H), 7.61 (d, J = 8 Hz, 2H, Ar-H), 7.80 (s, 1H, pyridine 
H), 8.09 (d, J = 8.0 Hz, 2H, Ar-H), 8.35 (d, J = 8.5 Hz, 2H, Ar-H), 8.44 (d, J = 8.5 Hz, 2H, Ar-
H); 13C NMR (125 MHz, DMSO-d6) δ ppm: 14.43, 64.35, 108.00, 119.40, 120.98, 127.91, 
128.42, 129.66, 130.36, 131.07, 133.78, 136.51, 136.54, 136.59, 138.53, 139.40, 142.98, 
147.32, 153.85, 155.51, 156.78, 160.55, 160.64; Calcd for C29H20Cl2N6O5S: C, 54.81; H, 3.17; 
N, 13.23. Found: C, 55.09; H, 3.30; N, 13.52.
4.4.3.7. 4-(3-Acetyl-8-(4-chlorophenyl)-6-(4-methoxyphenyl)-5-oxopyrido[2,3-
d][1,2,4]triazolo[4,3-a]pyrimidin-1(5H)-yl)benzenesulfonamide (16g): Yield: 35%, m.p.  
>300 ºC; 1H NMR (300 MHz, DMSO-d6) δ ppm: 2.68 (s, 3H, -COCH3), 3.85 (s, 3H, -OCH3), 
7.02 (d, J = 8.7 Hz, 2H, Ar-H), 7.45-7.48 (m, 4H, 2Ar-H + -SO2NH2, D2O exchangeable), 7.60 
(d, J = 8.7 Hz, 2H, Ar-H), 7.76 (s, 1H, pyridine H), 8.09 (d, J = 9.0 Hz, 2H, Ar-H), 8.34 (d, J 
= 7.8 Hz, 2H, Ar-H), 8.48 (d, J = 8.4 Hz, 2H, Ar-H); Anal. Calcd for C29H21ClN6O5S: C, 57.95; 
H, 3.52; N, 13.98. Found: C, 58.00; H, 3.76; N, 14.24.
4.4.3.8. Ethyl 8-(4-chlorophenyl)-6-(4-methoxyphenyl)-5-oxo-1-(4-sulfamoylphenyl)-1,5-
dihydropyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidine-3-carboxylate (16h): Yield: 47%, m.p.  
>300 ºC; 1H NMR (300 MHz, DMSO-d6) δ ppm: 1.31 (t, J = 7.2 Hz, 3H, -COOCH2CH3), 3.85 
(s, 3H, -OCH3), 4.43 (q, J = 6.9 and 7.2 Hz, 2H, -COOCH2CH3), 7.01 (d, J = 8.7 Hz, 2H, Ar-
H), 7.31-7.50 (m, 4H, 2Ar-H + -SO2NH2, D2O exchangeable), 7.60 (d, J = 8.7 Hz, 2H, Ar-H), 
7.75 (s, 1H, pyridine H), 8.08 (d, J = 8.4 Hz, 2H, Ar-H), 8.33 (d, J = 8.7 Hz, 2H, Ar-H), 8.44 
(d, J = 8.7 Hz, 2H, Ar-H); Anal. Calcd for C30H23ClN6O6S: C, 57.10; H, 3.67; N, 13.32; Found: 
C, 57.32; H, 3.86; N, 13.59.
4.4.3.9. 4-(3-Acetyl-8-(4-chlorophenyl)-6-(4-nitrophenyl)-5-oxopyrido[2,3-
d][1,2,4]triazolo[4,3-a]pyrimidin-1(5H)-yl)benzenesulfonamide (16i): Yield: 52%, m.p. >300 
ºC; 1H NMR (400 MHz, DMSO-d6) δ ppm: 2.67 (s, 3H, -COCH3), 7.52 (s, 2H, -SO2NH2, D2O 
exchangeable), 7.61 (d, J = 8.5 Hz, 2H, Ar-H), 7.72 (d, J = 8.5 Hz, 2H, Ar-H), 7.87 (s, 1H, 
pyridine H), 8.11 (d, J = 8.5 Hz, 2H, Ar-H), 8.32 (d, J = 8.5 Hz, 2H, Ar-H), 8.36 (d, J = 8.5 
Hz, 2H, Ar-H), 8.49 (d, J = 8.5 Hz, 2H, Ar-H); 13C NMR (100 MHz, DMSO-d6) δ ppm: 30.08, 
107.70, 118.89, 120.79, 123.29, 127.71, 129.46, 130.15, 130.34, 136.17, 136.44, 139.14, 
142.13, 142.84, 146.42, 147.40, 147.68, 152.61, 155.51, 160.08, 160.63, 187.79; Anal. Calcd 
for C28H18ClN7O6S: C, 54.60; H, 2.95; N, 15.92; Found: C, 54.86; H, 3.18; N, 15.83.
4.4.3.10. Ethyl 8-(4-chlorophenyl)-6-(4-nitrophenyl)-5-oxo-1-(4-sulfamoylphenyl)-1,5-
dihydropyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidine-3-carboxylate (16j): Yield: 63%, m.p. 
>300 ºC; 1H NMR (300 MHz, DMSO-d6) δ ppm: 1.24 (t, J = 6.6 Hz, 3H, -COOCH2CH3), 4.35 
(q, J = 6.9 and 7.6 Hz, 2H, -COOCH2CH3), 7.54 (s, 2H, -SO2NH2, D2O exchangeable), 7.62 
(d, J = 8.1 Hz, 2H, Ar-H), 7.74 (d, J = 7.5 Hz, 2H, Ar-H), 7.89 (s, 1H, pyridine H), 8.09 (d, J 
= 8.7 Hz, 2H, Ar-H), 8.32 (d, J = 7.5 Hz, 2H, Ar-H), 8.37 (d, J = 8.1 Hz, 2H, Ar-H), 8.44 (d, J 
= 8.7 Hz, 2H, Ar-H); Anal. Calcd for C29H20ClN7O7S: C, 53.92; H, 3.12; N, 15.18. Found: C, 
54.27; H, 3.36; N, 15.40.
4.4.3.11. 4-(3-Acetyl-6-(4-fluorophenyl)-5-oxo-8-(thiophen-2-yl)pyrido[2,3-
d][1,2,4]triazolo[4,3-a]pyrimidin-1(5H)-yl)benzenesulfonamide (16m): Yield: 53%, m.p.  
>300 ºC; 1H NMR (300 MHz, DMSO-d6) δ ppm: 2.66 (s, 3H, COCH3), 7.23-7.33 (m, 3H, 2Ar-
H + H4 thiophene), 7.49 (br. s, 2H, D2O exchangeable SO2NH2), 7.51 (d, J = 8.4 Hz, 2H, Ar-
H), 7.76 (s, 1H, pyridine H), 7.86 (m, 1H, H5 thiophene), 8.11 (d, J = 8.9 Hz, 2H, Ar-H), 8.15-
8.2 (m, 1H, H3 thiophene), 8.43 (d, J = 8.9 Hz, 2H, Ar-H); Anal. Calcd for C26H17FN6O4S2: C, 
55.71; H, 3.06; N, 14.99. Found: C, 55.86; H, 3.34; N, 15.28.
4.4.3.12. Ethyl 6-(4-fluorophenyl)-5-oxo-1-(4-sulfamoylphenyl)-8-(thiophen-2-yl)-1,5-
dihydropyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidine-3-carboxylate (16n): Yield: 48%, m.p. 
>300 ºC; 1H NMR (300 MHz, DMSO-d6) δ ppm: 1.29 (t, J = 7.2 Hz, 3H, -COOCH2CH3), 4.41 
(q, J = 7.2 and 7.5 Hz, 2H, -COOCH2CH3), 7.22-7.33 (m, 3H, 2Ar-H + H4 thiophene), 7.45-
7.53 (m, 4H, 2Ar-H +2H of SO2NH2, D2O exchangeable), 7.77 (s, 1H, pyridine H), 7.82-7.88 
(m, 1H, H5 thiophene), 8.10 (d, J = 8.4 Hz, 2H, Ar-H), 8.15-8.2 (m, 1H, H3 thiophene), 8.40 
(d, J = 8.4 Hz, 2H, Ar-H); Anal. Calcd for C27H19FN6O5S2 C, 54.91; H, 3.24; N, 14.23. Found: 
C, 55.26; H, 3.53; N, 14.56.
4.4.3.13. 4-(3-Acetyl-6-(4-chlorophenyl)-5-oxo-8-(thiophen-2-yl)pyrido[2,3-
d][1,2,4]triazolo[4,3-a]pyrimidin-1(5H)-yl)benzenesulfonamide (16o): Yield: 73%, m.p. >300 
ºC; 1H NMR (400 MHz, DMSO-d6) δ ppm: 2.67 (s, 3H, COCH3), 7.24 (m, 1H, H4 thiophene), 
7.48 (d, J = 8.4 Hz, 2H, Ar-H), 7.54-7.56 (m, 4H, 2Ar-H + 2H of SO2NH2, D2O exchangeable), 
7.79 (s, 1H, pyridine H), 7.88 (d, J = 4.5 Hz, 1H, H5 thiophene), 8.12 (d, J = 8.8 Hz, 2H, Ar-
H), 8.17 (d, J = 3.3 Hz, 1H, H3 thiophene), 8.45 (d, J = 8.8 Hz, 2H, Ar-H); 13C NMR (100 
MHz, DMSO-d6) δ ppm: 30.18, 107.24, 117.80, 120.95, 127.73, 128.22, 129.47, 129.94, 
130.71, 132.49, 133.47, 138.39, 139.16, 142.23, 142.83, 143.63, 147.37, 153.29, 155.32, 
157.27, 160.39, 188.08; Anal. Calcd for C26H17ClN6O4S2: C, 54.12; H, 2.97; N, 14.56. Found: 
C, 54.36; H, 3.26; N, 14.79.
4.4.3.14. Ethyl 6-(4-chlorophenyl)-5-oxo-1-(4-sulfamoylphenyl)-8-(thiophen-2-yl)-1,5-
dihydropyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidine-3-carboxylate (16p): Yield: 63%, m.p. 
286-289 oC; 1H NMR (300 MHz, DMSO-d6) δ ppm: 1.29 (t, J = 7.2 Hz, 3H, -COOCH2CH3), 
4.42 (q, J = 7.2 and 6.9 Hz, 2H, -COOCH2CH3), 7.24 (m, 1H, H4 thiophene), 7.46-7.51 (m, 
4H, 2Ar-H + 2H of SO2NH2, D2O exchangeable), 7.53 (d, J = 8.4 Hz, 2H, Ar-H), 7.77 (s, 1H, 
pyridine H), 7.87 (d, J = 4.8 Hz, 1H, H5 thiophene), 8.10 (d, J = 8.7 Hz, 2H, Ar-H), 8.16 (m, 
1H, H3 thiophene), 8.40 (d, J = 8.7 Hz, 2H, Ar-H); Calcd for C27H19ClN6O5S2: C, 53.42; H, 
3.15; N, 13.84. Found: C, 53.66; H, 3.47; N, 14.06.
4.4.3.15. 4-(3-Acetyl-6-(4-methoxyphenyl)-5-oxo-8-(thiophen-2-yl)pyrido[2,3-
d][1,2,4]triazolo[4,3-a]pyrimidin-1(5H)-yl)benzenesulfonamide  (16q): Yield: 64%, m.p. 
>300 ºC; 1H NMR (300 MHz, DMSO-d6) δ ppm: 2.63 (s, 3H, COCH3), 3.80 (s, 3H, -OCH3), 
6.97 (d, J = 9 Hz, 2H, Ar-H), 7.20 (m, 1H, H4 thiophene), 7.37-7.45 (m, 4H, 2Ar-H +2H of 
SO2NH2, D2O exchangeable), 7.56 (s, 1H, pyridine H), 7.74-8.06 (m, 3H , 2Ar-H + H5 
thiophene), 8.27 (m, 1H, H3 thiophene), 8.39 (d, J = 8.1 Hz, 2H, Ar-H); Calcd for 
C27H20N6O5S2: C, 56.63; H, 3.52; N, 14.68. Found: C, 56.93; H, 3.86; N, 14.37.
4.4.3.16. Ethyl 6-(4-methoxyphenyl)-5-oxo-1-(4-sulfamoylphenyl)-8-(thiophen-2-yl)-1,5-
dihydropyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidine-3-carboxylate (16r): Yield: 60%, m.p. 
>300 ºC; 1H NMR (300 MHz, DMSO-d6) δ ppm: 1.31 (t, J = 7.2 Hz, 3H, -COOCH2CH3), 3.85 
(s, 3H, -OCH3), 4.42 (q, J = 7.2 and 6.9 Hz, 2H, -COOCH2CH3), 7.01 (d, J = 8.7 Hz, 2H, Ar-
H), 7.23 (m, 1H, H4 thiophene), 7.41 (d, J = 8.7 Hz, 2H, Ar-H), 7.48 (br. s, 2H, SO2NH2, D2O 
exchangeable), 7.72 (s, 1H, pyridine H), 7.85 (d, J = 4.8 Hz, 1H, H5 thiophene), 8.09 (d, J = 
8.7 Hz, 2H, Ar-H), 8.13-8.20 (m, 1H, H3 thiophene), 8.40 (d, J = 8.7 Hz, 2H, Ar-H); 13C NMR 
(75 MHz, DMSO) δ 14.22, 55.70, 64.08, 107.21, 113.64, 117.84, 118.75, 120.92, 127.50, 
129.65, 130.46, 130.77, 131.55, 132.22, 136.37, 139.19, 142.73, 143.80, 147.07, 154.48, 
155.09, 156.68, 159.92, 160.64,; Calcd for C28H22N6O6S2: C, 55.81; H, 3.68; N, 13.95. Found: 
C, 55.54; H, 3.37; N, 14.09. 
4.4.3.17. 4-(3-Acetyl-6-(4-nitrophenyl)-5-oxo-8-(thiophen-2-yl)pyrido[2,3-
d][1,2,4]triazolo[4,3-a]pyrimidin-1(5H)-yl)benzenesulfonamide (16s): Yield: 69%, m.p. >300 
ºC; 1H NMR (300 MHz, DMSO-d6) δ ppm: 2.67 (s, 3H, COCH3), 7.25 (m, 1H, H4 thiophene), 
7.52-7.70 (m, 4H, 2Ar-H +2H of SO2NH2, D2O exchangeable), 7.86 (s, 1H, pyridine H), 8.00-
8.33 (m, 5H , 4Ar-H + H5 thiophene), 8.45-8.55 (m, 3H , 2Ar-H + H3 thiophene); Calcd for 
C26H17N7O6S2: C, 53.15; H, 2.92; N, 16.69. Found: C, 53.46; H, 3.24 N, 17.02.
4.4.3.18. Ethyl 6-(4-nitrophenyl)-5-oxo-1-(4-sulfamoylphenyl)-8-(thiophen-2-yl)-1,5-
dihydropyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidine-3-carboxylate (16t ): Yield: 72%, m.p. 
>300 ºC; 1H NMR (300 MHz, DMSO-d6) δ ppm: 1.28 (t, J = 7.2 Hz, 3H, -COOCH2CH3), 4.40 
(q, J = 7.2 and 6.9 Hz, 2H, -COOCH2CH3), 7.24 (t, J = 4.2 Hz, 1H, H4 thiophene), 7.50 (br. s, 
2H, SO2NH2, D2O exchangeable), 7.72 (d, J = 8.7 Hz, 2H, Ar-H), 7.83 (s, 1H, pyridine H), 
7.88 (d, J = 4.8 Hz, 1H, H5 thiophene), 8.10 (d, J = 8.7 Hz, 2H, Ar-H), 8.16-8.20 (m, 1H, H3 
thiophene), 8.32 (d, J = 8.4 Hz, 2H, Ar-H), 8.40 (d, J = 8.4 Hz, 2H, Ar-H); 13C NMR (75 MHz, 
DMSO-d6) δ ppm: 13.74, 63.60, 106.34, 117.00, 120.60, 122.82, 127.20, 128.89, 129.65, 
130.00, 132.31, 135.78, 138.54, 142.42, 143.02, 146.00, 146.72, 147.17, 151.64, 154.54, 
156.00, 157.00, 159.85; Calcd for C27H19N7O7S2: C, 52.51; H, 3.10; N, 15.88. Found: C, 52.63; 
H, 3.31; N, 15.64.
4.1. CA activity and inhibition measurements:
An Applied Photophysics stopped-flow instrument has been used for assaying the CA catalysed 
CO2 hydration activity.22 Phenol red (at a concentration of 0.2 mM) has been used as indicator, 
working at the absorbance maximum of 557 nm, with 20 mM Hepes (pH 7.5) as buffer, and 20 
mM Na2SO4 (for maintaining constant the ionic strength), following the initial rates of the CA-
catalyzed CO2 hydration reaction for a period of 10-100 s. The CO2 concentrations ranged from 
1.7 to 17 mM for the determination of the kinetic parameters and inhibition constants. For each 
inhibitor at least six traces of the initial 5-10% of the reaction have been used for determining 
the initial velocity. The uncatalyzed rates were determined in the same manner and subtracted 
from the total observed rates. Stock solutions of inhibitor (0.1 mM) were prepared in distilled-
deionized water and dilutions up to 0.01 nM were done thereafter with the assay buffer. Inhibitor 
and enzyme solutions were preincubated together for 15 min at room temperature prior to assay, 
in order to allow for the formation of the E-I complex. The inhibition constants were obtained 
by non-linear least-squares methods using PRISM 3 and the Cheng-Prusoff equation, as 
reported earlier,24 and represent the mean from at least three different determinations. All CA 
isofoms were recombinant ones obtained in-house as reported earlier. 25
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